Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopy Clear all
Completed Phase 4 Interventional

A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis

NCT00106496
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Protopic, Corticosteroid, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
24
States / cities
Birmingham, Alabama • Irvine, California • Loma Linda, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Not applicable Interventional Results available

Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema

NCT01326910
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Colloidal Oatmeal, Topical Cream
Drug · Device
Lead sponsor
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Industry
Eligibility
6 Months to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Miamiville, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2 Interventional

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

NCT05717920
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ADX-629 (Open-label)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

NCT05369403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Montgomery, Alabama • Phoenix, Arizona • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

NCT04845620
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.05%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 5 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
71
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

NCT03916081
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roflumilast Cream 0.05%, Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
17
States / cities
Scottsdale, Arizona • San Diego, California • Hialeah, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 24, 2026, 6:51 PM EDT
Recruiting Phase 2 Interventional

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07643766
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ENV-294, Placebo
Drug · Other
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Northridge, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 4 Interventional

A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis

NCT00666302
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
tacrolimus ointment, pimecrolimus cream
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
16 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

NCT02576938
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Baricitinib, Placebo, Triamcinolone (Optional)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 24, 2026, 6:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

NCT03847389
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Clobetasol propionate 0.05% Topical Oil
Drug
Lead sponsor
Hill Dermaceuticals, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Sanford, Florida • Savannah, Georgia • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 24, 2026, 6:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bathing Babies and Allergy

NCT03050658
View directory record Official record
Conditions
Atopic Dermatitis, Allergy
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
0 Hours to 72 Hours
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

NCT00832585
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Alefacept
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Oct 24, 2026, 6:51 PM EDT
Recruiting No phase listed Observational

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

NCT06732414
View directory record Official record
Conditions
Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Not applicable Interventional

A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis

NCT01675232
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Soak and smear, Dry Smear
Other
Lead sponsor
Yale University
Other
Eligibility
2 Weeks to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 24, 2026, 6:51 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Skin Barrier Assessment in Pregnancy and at Birth

NCT04445298
View directory record Official record
Conditions
Pregnancy Related, Allergy, Atopic Dermatitis Eczema, Asthma in Children, Food Allergy
Interventions
Transepidermal water loss, Skin tape stripping, Blood draw, Bacterial PCR swab
Diagnostic Test
Lead sponsor
National Jewish Health
Other
Eligibility
0 Minutes to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

NCT03921411
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Fountain Valley, California • Fremont, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

NCT02340234
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, TCS Cream
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pre-SunBeam TEWL AUC

NCT04226092
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GPSkin Barrier Pro, Aquaflux AF200
Device
Lead sponsor
Northwestern University
Other
Eligibility
0 Years to 3 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Denver, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 24, 2026, 6:51 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

NCT06808477
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BBT001, Placebo
Drug
Lead sponsor
Bambusa Therapeutics
Industry
Eligibility
18 Years to 72 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Irvine, California • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Early Phase 1 Interventional

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

NCT05891119
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab
Dietary Supplement · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 24, 2026, 6:51 PM EDT
Completed No phase listed Observational

Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

NCT03849716
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Blood sample, Cheek swab
Other
Lead sponsor
Sanofi
Industry
Eligibility
0 Years to 11 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Montgomery, Alabama • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 24, 2026, 6:51 PM EDT